N08, Glomerular disorders in diseases classified elsewhere
ICD-10-CM
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Documentation Required
- Medical records must document that the ultrasound was limited to retroperitoneal structures when billing CPT 76770/76775/76776, including images/findings demonstrating limitation to the retroperitoneum.
- If the exam was expanded to include organs outside the retroperitoneum, documentation must reflect the expansion and support billing a full or limited abdominal ultrasound (CPT 76700/76705/76706).
- Claims and documentation should follow the complementary Local Coverage Determination L34577 and any applicable LCD requirements.
- Claims must be supported by medical record documentation of the patient’s diagnosis/clinical condition and justification that the selected drug, dose, and route of administration are appropriate and medically necessary for the non-oncologic indication.
- Billing must comply with Medicare rules and any applicable LCD prior authorization or documentation requirements; follow any specific forms or prior authorization processes required by the LCD or payer.
- Refer to Local Coverage Determination L35026 for clinical coverage criteria, medical necessity requirements, and any required prior authorization; this article complements that LCD with billing/coding guidance.
Key Coverage Criteria
- Retroperitoneal ultrasound (CPT 76770, 76775, 76776) is covered when the exam is limited solely to retroperitoneal structures.
- A full (complete) or limited abdominal ultrasound (CPT 76700, 76705, 76706) is covered when the exam includes organs or structures outside the retroperitoneum or when primary findings involve non-retroperitoneal structures (e.g., gallbladder, liver, spleen, common bile duct).
- Anti-neoplastic (chemotherapy) agent CPT/HCPCS codes may be used to bill for administration of these drugs when given to treat non-oncologic (noncancer) diagnoses if the drug is medically necessary for the patient’s condition and consistent with the standard of medical practice.
- Monoclonal antibody agents and other biologic response modifiers may be administered and billed using chemotherapy administration codes for noncancer indications when the dose, route, and clinical use are appropriate and medically necessary.
- Chemotherapy agents are covered when medically necessary, the drug is FDA-approved for the indication, and the drug is listed in the NCCN Clinical Practice Guidelines for the specific ICD-10 diagnosis being treated with an NCCN category 1 or 2A listing and used per the NCCN Recommended Use (order or combination).
- Chemotherapy agents are covered when medically necessary if the indication is listed in an alternative Medicare‑approved compendium at an accepted level: Micromedex DrugDex Class I, IIa, or IIb; AHFS narrative text 'supportive'; Clinical Pharmacology narrative text 'supportive'; or Lexi-Drugs listed as 'Use Off-Label' with evidence level A.
6 Active Policies
WPS-J5-L37205, Chemotherapy Drugs and their Adjuncts
J5
A55639, Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
J5
WPS-J8-L37205, Chemotherapy Drugs and their Adjuncts
J8
A55336, Billing and Coding: Retroperitoneal Ultrasound
A56380, Billing and Coding: Rituximab
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.